About Us


Strategic Healthcare Investment Partners (S.H.I.P.) was established in 2018 to focus on medical device and digital health innovation targeting large unmet needs.


CONTACT US


About Us


Strategic Healthcare Investment Partners (S.H.I.P.) was established in 2018 to focus on medical device and digital health innovation targeting large unmet needs.


CONTACT US

Brad H. Vale, who previously led Johnson & Johnson’s venture arm, JJDC, and Mudit K. Jain, previously with Synergy Life Science Partners, established Strategic Healthcare Investment Partners (S.H.I.P.) in 2018 to focus on medical device and digital health innovation targeting large unmet needs.


WE ARE FOUNDERS, OPERATORS, COMPANY BUILDERS, AND INVESTORS

The S.H.I.P team brings more than 80 years of cumulative healthcare experiences in investing and operational roles. We have invested globally in more than 60 companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming S.H.I.P. We bring a unique set of investing experiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top performing venture capital fund that generated multiple medical device Unicorns.

The S.H.I.P team has been involved in some of the premium healthcare companies bringing novel technologies to market. With over 80 years of combined operational and investing experiences across early and commercial stage companies, the S.H.I.P team has played and active and important role from founding companies to liquidity via trade sales to multiple strategics and IPOs. Our experiences on private company and public company boards gives us a unique vantage point in our active involvement with portfolio companies. In addition, our scientific and commercial backgrounds along with global relationships have helped us play an important role in consistently building some of the most successful healthcare companies over last two decades.


REPRESENTATIVE INVESTMENTS

iRhythm
Aptus Endosystems
Biosense Webster
23andMe
ilypsa
Atrionix Inc.
ShiraTronics
CVR
Hyalex
NeoChord

CLEAR FOCUS & NOVEL STRATEGY

We focus on medical technology investments in companies targeting large unmet clinical needs. We will invest in high growth areas and in companies solving major clinical problems while balancing that with focused capital efficient development plans. We take a balanced approach in building our portfolio with some early stage investments, where the prior seed stage investment has proved the feasibility of a concept, and some later stage investments, where clinical data has shown efficacy and the company is in a “scale up for commercialization” mode.

Our presence in US and Ireland provides a large geographical footprint to support healthcare innovation globally.

We also invest in opportunities generated by NuXcel, our own medical device accelerator with a presence in Silicon Valley, Minneapolis, and Ireland.

S.H.I.P. leverages its relationships and unique set of LPs to improve the speed and quality of development of new products and their commercialization globally.

SAN FRANCISCO   |   IRELAND


SAN FRANCISCO   |   IRELAND


Copyright 2020 Strategic Healthcare Investment Partners. All rights reserved.